Asset profile
FOR46
Antibody–drug conjugate
Evidence outlook · lead readout
NCT03650491 · Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03650491: This was an uncontrolled, unblinded dose-finding study with no placebo or comparator arm, so any response seen cannot be confidently attributed to the drug; results have not been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.